Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Eyenovia Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
EYEN
Nasdaq
2834
https://eyenovia.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Eyenovia Inc
Eyenovia (EYEN) Down 18% on Disappointing Corporate Update
- Apr 9th, 2024 1:29 pm
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
- Apr 8th, 2024 11:00 am
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings
- Apr 3rd, 2024 11:00 am
Q4 2023 NovaBay Pharmaceuticals Inc Earnings Call
- Mar 27th, 2024 1:57 pm
Eyenovia, Inc. (NASDAQ:EYEN) Q4 2023 Earnings Call Transcript
- Mar 19th, 2024 12:50 pm
Q4 2023 Eyenovia Inc Earnings Call
- Mar 19th, 2024 10:41 am
Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates
- Mar 18th, 2024 9:20 pm
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
- Mar 18th, 2024 8:05 pm
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
- Mar 13th, 2024 11:00 am
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
- Mar 11th, 2024 11:00 am
Beyond Cataract Surgery: Analyst Highlights Broader Market Potential For Eyenovia/Formosa's Steroid For Post-Eye Surgery Pain, Inflammation
- Mar 5th, 2024 5:59 pm
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
- Mar 5th, 2024 1:00 pm
UPDATE 2-US FDA approves Eyenovia's eye drug, Formosa Pharma says
- Mar 4th, 2024 11:21 pm
retail investors who own 56% along with institutions invested in Eyenovia, Inc. (NASDAQ:EYEN) saw increase in their holdings value last week
- Mar 1st, 2024 10:04 am
Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
- Feb 13th, 2024 12:00 pm
Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada
- Jan 16th, 2024 12:00 pm
7 Promising Penny Stocks With the Potential to Defy Expectations
- Dec 15th, 2023 1:17 pm
Eyenovia, Inc. (NASDAQ:EYEN) Q3 2023 Earnings Call Transcript
- Nov 14th, 2023 3:38 pm
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 13th, 2023 9:05 pm
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
- Nov 9th, 2023 12:05 pm
Scroll